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Background/aim: Scars develop at the end of the natural wound-healing process and are characterized by excessive collagen deposition,
particularly types I and III collagen. This study aimed to investigate the genetic association of COL1A1 −1997 G/T (rs1107946) and
COL1A1 Sp1 +1245 G/T (rs1800012) polymorphisms with the incidence of scars.
Materials and methods: A case-control association study was conducted with 84 volunteers from Jeddah, Saudi Arabia (47 patients and
37 controls). The allele frequency distribution and nucleotide genotypes of −1997 G/T, +1245 G/T were ascertained by polymerase chain
reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis.
Results: Our results indicated that the distribution of COL1A1 (rs1107946) genotypes was significantly different between patients and
controls (P = 0.00). The incidence of COL1A1 (rs1107946) genotype GG was significantly associated with a risk of scars. The distribution
of the (rs1107946) genotype was drastically higher in women with scars (P= 0.00). One haplotype block in COL1A1 was documented
by the pair-wise linkage disequilibrium between the single nucleotide polymorphisms (SNPs). The frequency of the GG haplotype
constructed by the two SNPs was robustly high and associated with risk of scars.
Conclusion: Our results strengthen the evidence for the association between polymorphisms of −1997 G/T, +1245 G/T of the COL1A1
gene in the genetic etiology of keloid scars.
Key words: Keloid, collagen, COL1A1, restriction fragment length polymorphism, polymerase chain reaction, single nucleotide
polymorphism

1. Introduction
Keloid scars are benign fibroproliferative cutaneous lesions
resulting from the overproduction of all components of
the healing process, including fibroblasts, collagen, elastin,
and proteoglycans; they can occur following burn injuries,
lacerations, abrasions, surgery, piercings, vaccinations,
and even minor skin trauma. They are unique in humans,
and especially in genetically susceptible individuals from
nonwhite populations (1–3). It has been estimated that
about 15%–20% of Blacks, Hispanics, and Orientals suffer
from keloids and there appears to be a genetic predisposition
to keloid formation (4). Keloids can develop at every age,
but they have a higher incidence between 10 and 30 years
(1,3). A slight female predominance is also noted, but this
could be related to the higher rate of earlobe piercing in
females (3,5). The incidence rates of hypertrophic scarring
vary from 40% to 70% following surgery to up to 91%
following burn injuries (4). The alterations responsible for
keloid formation are still unknown, but it is thought that
* Correspondence: sanaa_t@hotmail.com
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injury to the reticular layer of the dermis, which consists
mainly of collagen and fibroblasts, can contribute to the
formation of keloids. The end result of this is the failure
of wound healing and accumulation of excess matrix and
collagen, called scarring (2,6,7).
Collagen consists of triple helix proteins and represents
approximately 70% of the dry weight of the human skin
(8–10). The prominent collagens are types I and III. Type
I collagen constitutes 80%–90% and type III constitutes
10%–15% of the total collagen present in the skin (9).
In humans the gene coding for the α 1 chain of type I
collagen is located on the long arm of chromosome 17
(17q21.3-q22), has a size of 18 kb, and consists of 51 exons
(12,13). The transcription of COL1A1 of type I collagen
is regulated by the promoter and the first intron (12).
The absolute amount of collagen increases in keloids,
indicating increased collagen synthesis or decreased cross
linking; mature scars have a higher content of cross linked
collagen than keloids (2,13).
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There is a common single nucleotide polymorphism
(SNP) in the specificity protein 1 (Sp1) binding site within
the promoter region of intron 1 of COL1A1 (1). Most studies
of COL1A1 have focused on the polymorphism that affects
the Sp1 binding site in the first intron at position +1245
(rs1800012) (G/T). More recently, two polymorphisms
have been identified in the proximal promoter of
COL1A1 at positions –1997 (rs1107946) (G/T) and –1663
(rs2412298) (indel T). These polymorphisms have been
associated with bone mineral density (BMD) in several
studies, and in some populations have been reported to
interact with the Sp1 polymorphism to regulate BMD
(14–16).
The current study was designed to evaluate the
association of −1997 G/T (rs1107946) and COL1A1
Sp1 +1245 G/T (rs1800012) of the COL1A1 gene
polymorphisms with the incidence of scars in a Jeddah
population in Saudi Arabia. Genomic DNA extraction
from the collected samples was performed, followed
by polymerase chain reaction (PCR) amplification
with specific primers, and then restriction fragment
length polymorphism (RFLP) analysis, sequencing, and
alignment of the obtained sequence. Statistical analysis
and data interpretation were carried out in the patients
with scars and in the normal group.
2. Materials and methods
2.1. Study of the population
A total of 84 participants were recruited, 47 patients with
scars (25 men and 24 women) and 37 healthy controls (19
men and 18 women), with ages ranging from 7 to 60 years
old. The patients with scars consisted of 32 individuals
with keloid scars and 15 with hypertrophic scars. The
scar samples were collected from the plastic surgery clinic
of King Fahad Hospital, the Military Forces Hospital,
and the tissue culture unit in the King Fahad Medical
Research Center in Jeddah. These samples were evaluated
by a clinician based on the following clinical criteria:
hypertrophic scars tend to be red and raised scars, limited
to the borders of the original lesion, and often presenting
contractures; keloid scars are raised, sometimes painful
and pruritic, and are not limited to the borders of the
original lesion. Seven samples from circumcision surgeries
at the Maternity Hospital Surgical Clinic in Jeddah and 30
blood samples from students at King Abdulaziz University
were obtained as normal samples. This study was approved
by the Ethical Committee Unit of Biomedical Ethics,
affiliated with the Directorate of Health Affairs, Jeddah,
and informed consent was obtained from each participant.

2.2. Genotyping study
Blood samples were collected into tubes containing the
anticoagulant ethylenediamine tetraacetic acid, tissue
samples were collected in normal saline, and cell cultures
were collected in 1.5-mL microcentrifuge tubes containing
200 µL of potassium phosphates PBS. The samples were
then stored at 4 °C until used.
Genomic DNA was extracted from whole samples
using the QIAamp DNA Mini Kit (QIAGEN) according
to the manufacturer’s instructions. The concentration of
genomic DNA was determined using a Jenway 6800 UV/
Visible spectrophotometer (JENWAY).
Primer sets were designed to amplify fragments
encompassing the SNPs. The primers used for genotyping
of polymorphisms in –1997 G/T of COL1A1 (rs1107946)
and Sp1 +1245 G/T of COL3A1 (rs1800012) are listed
in Table 1. Amplification was carried out using a
programmable thermal cycler PCR instrument (Eppendorf
Master Cycler Personal, Eppendorf AG). A final volume of
50 µL was prepared as follows: 2 µL (0.2 µg/µL) of genomic
DNA, 25 µL of Hot Start Green Master Mix (Promega),
22 µL of nuclease-free water, and 2.5 pmol of each primer.
Thermal cycling conditions for –1997 G/T (rs1107946)
and +1245 G/T (rs1800012) are given in Table 1. The
–1997 G/T (rs1107946) and Sp1 +1245 G/T (rs1800012)
SNPs in the COL1A1 gene were analyzed by PCR
amplification, followed by RFLP analysis. The genotypes of
these SNPs were determined by DNA digestion using BsaI
(New England BioLabs, Inc.) for –1997 G/T (rs1107946)
and PflMI (New England BioLabs, Inc.) for +1245 G/T
(rs1800012). Results were visualized on 3% (w/v) agarose
gel electrophoresis. Sequencing was performed following
the instructions of the BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems) and using the Sanger
dideoxy sequencing method.
2.3. Haplotype structure and statistical analysis
The data analysis was performed using SPSS for Windows,
version 16 (SPSS Inc.). Descriptive data are given as means
± standard deviation (SD). Associations between groups
and genotypes were assessed using the nonparametric
Mann–Whitney test. A 2-by-3 chi-square test was applied
to test the association between genotypes and clinical
groups, and a 2-by-2 test was used to test the association
between alleles in clinical groups. Contingency analysis
was applied to calculate the odds ratio (OR) and risk
ratio (RR) at a 95% confidence interval (CI) to estimate
the relative risk and strength of association for the various
genotypes or their combinations. Statistical significance
was defined as P < 0.05. The Hardy–Weinberg equilibrium
was tested by a goodness-of-fit χ2 test to compare the
observed genotype frequencies with the expected genotype
frequencies among the scar patients and the normal group,
with the chi-square test featuring one degree of freedom.
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Table 1. Restriction enzymes employed to distinguish between alleles and primers used to amplify genomic DNA around the
polymorphic sites in COL1A1 –1997 and +1245.
Site of polymorphism

Primer sets
(5’￫3’)

Annealing
temperature (°C)

Allele size
(bp)

Ref.

BsaI –1997 G/T (rs1107946)
Genomic DNA

TCACTAACCCTCATACTACCAAGC
CCCGACCATGTGGCAGCA

61

G: 151+124
T: 275

(16)

PflMI +1245 G/T (rs1800012)
Genomic DNA

CCAATCAGCCGCTCCCATTC
CATCGGGAGGGCAGGCTC

60

G: 99+57
T: 156

(1)

3. Results
3.1. Characteristics of the population and genotyping
The average age and SD of the participants was 27.06 ±
13.17 years old and 19.62 ± 18.59 years old for the scar
patients and the normal group, respectively. The results
showed that there was a significant difference between
the patients with scars and the normal group in terms
of age (P = 0.03) (data not shown). For the –1997 G/T
COL1A1 rs1107946 polymorphism genotyping, the T
allele produced 270 bp, the G allele formed fragments of
151 bp and 124 bp, the G allele of +1245 G/T COL1A1
rs1800012 created fragments of 99 and 57 bp, and the T
allele produced 156 bp (Figures 1 and 2). Direct DNA
sequence analysis of the amplified PCR products revealed
T/G and G/G substitutions at –1997 (rs1107946) of the
COL1A1 gene (Figures 3A and 3B).
The prevalence of each genotype of the COL1A1 −1997
G/T (rs1107946) was 37.8% for GG, 62.2% for GT, and
0.0% for TT for healthy controls, and 66% for GG, 29.8%
for GT, and 4.2% for TT for the patients with scars. For
the COL1A1 +1245 G/T (rs1800012), the prevalence was
67.6% for GG, 32.4% for GT, and 0.0% for TT for the
controls, and 49.9 for GG, 51.5% for GT, and 0.0% for
TT for the patients with scars (Table 2). These genotype
distributions were in the Hardy–Weinberg equilibrium. It
A

M
M

11

22

33

275 bp
151 bp
124 bp

Figure 1. A photograph of 3% (w/v) agarose gel showing the
digested PCR products for –1997 G/T COL1A1 polymorphism
genotyping. Lane M: DNA marker; lane 1: homozygous TT, the
genotype that produces one 275-bp band; lane 2: heterozygous
GT, the genotype that produces three bands, a 275-bp band, a
151-bp band, and a 124-bp band; lane 3: homozygous GG, the
normal genotype that produces two bands, a 151-bp band and a
124-bp band.

is remarkable that all obtained results of the +1245 G/T
polymorphism significantly illustrated the absence of
allele TT in all subjects (Table 2).
B

Figure 2. A photograph of a 3% (w/v) agarose gel showing the digested PCR products for +1245 G/T COL1A1 polymorphism genotyping.
Lane M: DNA marker; lanes 1 and 2: heterozygous GT, the genotype that produces three bands, a 156-bp band, a 99-bp band, and a 57bp band; lane 3: homozygous GG, the normal genotype that produces two bands, a 99-bp band and a 57-bp band.
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M

1

2

156 bp

99 bp
57 bp

Figure 3. (A) Sequence analysis of –1663 to –1997 in the
COL1A1 gene (a normal case). The box indicates T/G nucleotide
substitution. (B) Sequence analysis of –1663 to –1997 in the
COL1A1 gene (a scar case). The box indicates two copies of G
allele.

There was a highly significant difference in genotype
distribution and allele frequencies of the −1997 G/T
(rs1107946) polymorphism between the patients with
scars and the normal group using the 2-by-3 general
test of association (P = 0.00), which means that most of
the patients with scars tended to have the GG genotype
and most of the normal subjects tended to have the GT
genotype. The OR and the RR were 0.28 (95% CI: 0.11–
0.69). In contrast, no significant association was noted
between the genotype and the subject group (patients
with scars or normal subjects) (P = 0.08) for the +1245
G/T SNP. The OR and RR were 2.17 (95 % CI: 0.89–5.32)
(Table 2). The genotype distributions of polymorphism
met the Hardy–Weinberg expectations in both groups (the
patients with scars and the normal group) for the –1997
G/T SNP (P = 0.006) and for the +1245 G/T SNP (P =
0.01) (Table 2).
The frequencies of G and T alleles for the scar group
were 80.9% and 19.1%, respectively, while for the normal
group they were 68.9% and 31.1%, respectively. Thus, the
results demonstrated that there was a significant difference
in allele frequencies between the scar group and the
normal group for the –1997 G/T SNP (P = 0.05) (Table
2). In the case of the +1245 G/T SNP, the frequencies of

Table 2. The association between the presence of COL1A1 –1997 G/T (rs1107946) or +1245 G/T (rs1800012) polymorphisms and the
incidence of scars.

SNP

–1997
G/T
(n = 84)

+1245
G/T
(n = 84)

Group

Normal
(n = 37)

COL1A1 genotype distribution
GG

GT

(n = 14)
37.8%

(n = 23)
62.2%

Scar
(n = 47)

(n = 31)
66%

(n = 14)
29.8%

Normal
(n = 37)

(n = 25)
67.6%

(n = 12)
32.4%

Scar
(n = 47)

(n = 23)
48.9%

(n = 24)
51.1%

TT
(n = 0)

(n = 2)
4.2%

(n = 0)

(n = 0)

Allele frequency HWE

P-valuea

P-valueb

P-valuec

0.02**

0.00**

0.05*

0.08

0.08

0.14

G: 68.9%
(n = 51 )
T: 31.1%
(n = 23)

0.006

G: 80.9%
(n = 76 )
T: 19.1%
(n = 18 )

0.79

G: 83.8%
(n = 62)
T: 16.2%
(n = 12)

0.23

G: 74.5%
(n = 70)
T: 25.5%
(n = 24)

0.01

n: number of samples, HWE: Hardy–Weinberg equation.
P-valuea: expressed as frequencies, and were compared by the Mann–Whitney test.
P-valueb: correspond to genotype distribution using a 2-by-3 chi-square test.
P-valuec: correspond to allele frequency using a 2-by-2 chi-square test.
*
**
Significance (P = 0.05);
Highly significant results (P < 0.05).
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G and T alleles for the scar group were 74.5% and 25.5%,
respectively, while for the normal group they were 83.8%
and 16.2%, respectively; no significant difference in allele
frequencies between the scar group and the normal
group was observed (P = 0.07) (Table 2). The association
between the presence of −1997 G/T (rs1107946) or +1245
G/T (rs1800012) polymorphisms and the incidence of
scars is shown in Table 2. A highly significant difference
in variation among genotypes (P = 0.02) between the scar
group and the normal group was found in the –1997 G/T
SNP, while no significant difference (P = 0.08) was found
in the +1245 G/T SNP.
In addition, the association between the presence of
either −1997 G/T (rs1107946) or +1245 G/T (rs1800012)
polymorphisms and the incidence of scars in male patients
were studied (Table 3). The genotype distributions of
polymorphism met the Hardy–Weinberg expectations in
both groups (males with scars and normal males) (P = 0.23
in the –1997 G/T SNP, 0.36 in the +1245 G/T SNP). No
significant difference in variation among the genotypes (P
= 0.51 in –1997 G/T) and (P = 0.22 in +1245 G/T) was
observed between males with scars and normal males
(Table 3). The distribution of genotypes among the scar
group in the –1997 G/T SNP was 66.7% homozygous GG (n

= 16), 25% heterozygous GT (n = 6), and 8.3% homozygous
TT (n = 2), while among the normal group it was 52.6%
homozygous GG (n = 10), 47.4% heterozygous GT (n =
9), and the homozygous recessive TT was undetected in
this group as shown in Table 3. For the +1245 G/T SNP,
the distribution of genotypes among the scar group was
50% homozygous GG (n = 12) and 50% heterozygous
GT (n = 12), while among the normal group it was 68.4%
homozygous GG (n = 13) and 31.6% heterozygous GT
(n = 6). The homozygous recessive TT was undetected in
both groups as shown in Table 3. Therefore, there was no
significant difference in genotype distribution and allele
frequencies of the −1997 G/T (rs1107946) polymorphism
between the scar and the normal male groups (P = 0.17
in –1997 G/T) and (P = 0.22 in +1245 G/T). Moreover,
the results demonstrated that there was no significant
difference in allele frequencies between male patients with
scars and normal male subjects (P = 0.75 for –1997 G/T)
and (P = 0.29 for +1245 G/T).
The association between the presence of −1997 G/T
(rs1107946) or +1245 G/T (rs1800012) polymorphisms
and the incidence of scars in female patients is shown in
Table 4. The genotype distributions for polymorphism met
the Hardy–Weinberg expectations in both groups (females

Table 3. An association between the presence of COL1A1 –1997 G/T (rs1107946) or +1245 G/T (rs1800012) polymorphisms and the
incidence of scars in males.

SNP

–1997
G/T
(n = 43)

+1245
G/T
(n = 43)

Group

Normal
(n = 19)

COL1A1 genotype distribution
GG

GT

(n = 10)
52.6%

(n = 9)
47.4%

Scar
(n = 24)

(n = 16)
66.7%

(n = 6)
25%

Normal
(n = 19)

(n = 13)
68.4%

(n = 6)
31.6%

Scar
(n = 24)

(n = 12)
50%

(n = 12)
50%

TT
(n = 0)

(n = 2)
8.3%

(n = 0)

(n = 0)

Allele
frequency

P-valuea

P-valueb

P-valuec

0.51

0.17

0.75

0.22

0.22

0.29

G: 76.3%
(n = 29 )
T: 23,7%
(n = 9)

0.17

G: 79.2%
(n = 38 )
T: 20.8%
(n = 10 )

0.23

G: 84.2%
(n = 32)
T: 15.8%
(n = 6)

0.36

G: 75%
(n = 36)
T: 25%
(n = 12)

n: number of samples.
HWE: Hardy–Weinberg expectations.
P-valuea: expressed as frequencies, and were compared by Mann–Whitney test.
P-valueb: correspond to genotype distribution using a 2-by-3 chi-square test.
P-valuec: correspond to allele frequency using a 2-by-2 chi-square test.
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Table 4. An association between the presence of COL1A1 –1997 G/T (rs1107946) or +1245 G/T (rs1800012) polymorphisms and the
incidence of scars in females.

SNP

–1997
G/T
(n = 41)

+1245
G/T
(n = 41)

Group

COL1A1 genotype distribution
GG

GT

Normal
(n = 18)

(n = 4)
22.2%

(n = 14)
77.8%

Scar
(n = 23)

(n = 15)
65.2%

(n = 8)
34.8%

Normal
(n = 18)

(n = 12)
66.7%

(n = 6)
33.3%

Scar
(n = 23)

(n = 11)
47.8%

(n = 12)
52.2%

TT
(n = 0)

(n = 0)

(n = 0)

(n = 0)

Allele
frequency

HWE

P-valuea

P-valueb

P-valuec

0.00**

0.00**

0.02**

0.23

0.22

0.30

G: 61.1%
(n = 22 )
T: 38.9%
(n = 14)

0.008

G: 82.6%
(n = 38)
T: 17.4%
(n = 8 )

0.09

G: 83.4%
(n = 30)
T: 16.6%
(n = 6)

0.39

G: 73.9%
(n = 34)
T: 26.1%
(n = 12)

0.03

n: number of samples.
HWE: Hardy–Weinberg expectations.
P-valuea: expressed as frequencies, and compared by the Mann–Whitney test.
P-valueb: correspond to genotype distribution using a 2-by-3 chi-square test.
P-valuec: correspond to allele frequency using a 2-by-2 chi-square test.
**
Highly significant results (P < 0.05).

with scars and normal females) (P = 0.008 in the –1997
G/T SNP) and (P = 0.03 in the +1245 G/T SNP).There
was a highly significant difference in variation among
genotypes in the –1997 G/T SNP (P = 0.00) between
female patients with scars and normal females; however,
no significant difference in variation among genotypes in
+1245 G/T (P = 0.23) was found between these groups.
Furthermore, the distribution of genotypes in the scar
group was 65.2% homozygous GG (n = 15) and 34.8%
heterozygous GT (n = 8), while in the normal group it was
22.2% homozygous GG (n = 4) and 77.8% heterozygous
GT (n = 14). The homozygous recessive TT was undetected
in both groups. In the +1245 G/T SNP, the distribution of
genotypes in the scar group was 47.8 % homozygous GG
(n = 11) and 52.2 % heterozygous GT (n = 12), while in
the normal group it was 66.7% homozygous GG (n = 12)
and 33.3 % heterozygous GT (n = 6). The homozygous
recessive TT was undetected in both groups. When the
results in the two female groups were compared, a highly
significant association between groups and genotypes was
observed (P = 0.00) in –1997 G/T; there was no significant
association between groups and genotypes in +1245 G/T

(P = 0.22). Furthermore, a highly significant difference
in allele frequencies between the scar and the normal
group in females was detected (P = 0.02) in the –1997 G/T
SNP, while there were no significant differences in allele
frequencies between the scar and the normal group ( P=
0.30) in the +1245 G/T SNP (Table 4).
3.2. Haplotype analysis
When we combined the two polymorphisms together, we
found five −1997 G/T, +1245 G/T genotype alleles (GGGG,
GTGG, GGGT, GTGT, and TTGG) in our population. The
other genotypes (GGTT, GTTT, TTGT, and TTTT) were
undetected. Genotype combination frequencies for all
subjects are presented in Table 5. It is obvious that there
was a strong association in terms of linkage disequilibrium
(LD) between the –1997 G/T (rs1107946) and +1245
G/T (rs1800012) polymorphisms (P = 0.001). From the
obtained results, we found that the haplotype GG (−1997
G, +1245 G) was the most common (with a frequency
of 63.10%). The frequency of the rare haplotype TT was
8.93%. Haplotype analysis yielded a highly significant
association with scars (P = 0.005, Table 6).
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Table 5. Genotype frequencies for both polymorphisms in all 84 subjects.
Genotype

Derived alleles

N

Frequency (%)

X2

Alleles

N

GGGG

GG/GG

24

28.57

10.8194

GG

106

GGGT

GG/GT

21

25

GT

26

GTGG

GT/GG

22

26.19

TG

21

GTGT

GT/GT

15

17.86

TT

15

TTGG

TT/GG

2

2.38

84

100%

Total

168

Data are presented as the number of samples and the frequency.
X2 indicated a significant value in genotype data at P = 0.001.
Table 6. Linkage disequilibrium (LD) and inferred haplotype frequencies for COL1A1 −1997 G/T and +1245 G/T in all subjects.

SNP1

–1997 G/T (rs1107946)

SNP2

+1245 G/T (rs1800012)

–1

D’

0.088

r2

7.39

X2

Haplotype
Haplotype

Frequency (%)

GG
GT
TG
TT
Total

63.10
12.50
15.48
8.93
100

D’ = the deviation of the observed frequency of a haplotype from the expected.
X2 = 7.39 indicated that there were significantly higher frequencies of the COL1A1 allele haplotypes in the subjects (P = 0.005).

4. Discussion
Until now, the mechanism of keloid formation remains
unknown, underscoring the vital need to understand
and control these disfiguring maladaptive processes,
characterized by excessive collagen accumulation. Many
previous studies of alleles in relation to osteoporosisrelated phenotypes focused on the intron 1 Sp1 binding
site polymorphism (16). A promoter polymorphism,
–1997 G/T, was also associated with BMD (17). To date, no
published studies have investigated the association between
the –1997 G/T, +1245 G/T COL1A1 polymorphisms and
keloid disease.
The present study was undertaken to clarify the
genetic factors associated with susceptibility to keloid,
elucidate the molecular mechanisms for keloid formation,
and investigate the relation between –1997 G/T, Sp1
+1245 G/T in the regulatory region of the COL1A1 gene
polymorphisms and the prevalence of scars in Jeddah. The
obtained results demonstrate that there was a significant
difference across genotypes in the scar group, as compared
with the normal group, in the –1997 G/T polymorphism,
while no association was found between the +1245 G/T
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polymorphism and the incidence of scars. The –1997 G/T
and +1245 G/T polymorphisms were associated with
BMD in several studies. Our results were in agreement
with bone studies (18) in which a significant association
between perimenopausal bone mass and –1997 G/T
was shown, but no association between the +1245 G/T
polymorphism and peri- or postmenopausal bone mass
could be demonstrated.
On the other hand, our findings differed from results
reported in Denmark in which +1245 G/T was found to
have a negative influence on BMD, whereas –1997 G/T was
not significantly associated with BMD (14). Furthermore,
the present results were in disagreement with those
reported in the Rotterdam study (17), which indicated that
the COL1A1 Sp1 polymorphism influenced BMD and the
risk of fracture in postmenopausal Caucasian women. In
contrast, no independent effect of the –1997 G/T promoter
polymorphism on BMD or fractures was detected. A
recent study showed that the COL1A1 gene was associated
with reduced anterior cruciate ligament (ACL) injury
in professional soccer players and found no association
between the COL1A1 −1997 G/T polymorphism and the
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incidence of ACL ruptures; the COL1A1 gene was found
to be in high degree of LD with the +1245 G/T loci (19).
A higher frequency distribution of the COL1A1 –1997
GG genotype has been shown to be associated with scar
formation. The GG genotype was significantly higher in
the scar group than in the normal one (P = 0.00). The
combined analysis of two studies (16,20) suggested that
the GG genotype association with BMD was reduced in TT
homozygotes compared with the other genotype groups.
In the Sp1 +1245 G/T SNP, our results were in
accordance with those reported by González-Bofill et al.
(18). On the other hand, Enoch and Leaper (13) conducted
a study in Denmark on the association of promoter and
intron 1 polymorphisms of COL1A1 gene haplotypes with
increased risk of osteoporosis and found that the T-allele
of the +1245 G>T polymorphism was associated with a
decrease in BMD (P = 0.02). They suggested that alleles at
the Sp1 site (+1245 G/T) interact with alleles at the –1997
G/T site to regulate BMD (16).
When the subjects were divided by sex, the obtained
results were in agreement with the Rotterdam study that
found no association between the Sp1 or the –1997 G/T
polymorphisms with BMD or fractures in men (17). The
SNP rs1107946 was found to be only significant in females
but not in males.
In a study of 308 postmenopausal Caucasian women
from the United States, the –1997 and +1245 G/T
polymorphisms were found to be associated with BMD,
such that higher values were found in carriers of the G
allele at both polymorphic sites (21). These observations
were in agreement with the present observations in
–1997 G/T, but not in +1245 G/T. Another study of 1100
Japanese postmenopausal women reported a significant
association between –1997 G/T alleles and BMD in GG
homozygotes (22). Furthermore, a study in India showed
that an allele affecting BMD was exhibited by the major
allele (G) of –1997 G/T and the minor allele (T) of +1245
G/T (23), whereas a population of Chinese women showed
no association between –1997 G/T alleles and BMD (24).
Other studies (8,25) reported higher BMD values in
relation to the –1997 T allele in Japanese postmenopausal
women. In contrast, studies in Spanish and American
postmenopausal women reported that the –1997 T
allele was associated with reduced BMD (16,17,21). The
differences between these studies could be due to the
fact that the polymorphisms studied here are in LD with
other functional polymorphisms at the COL1A1 locus that
regulate BMD and that the patterns of LD differ in these
different populations (16).
In the present study, two locus haplotypes were tested
for an association with the scars. It was assumed that
the predisposition for scars might be a polygenic trait;
therefore, the haplotypes in two candidate polymorphisms

would provide more information than those in any single
polymorphism on the complex relationship between
DNA sequence variations and traits. In fact, studies have
shown that haplotype analysis is more powerful when the
genotypes are in LD with the causative locus (19).
The present results showed also that the GG haplotype
(with an estimated frequency among subjects of 65.96%)
was significantly higher in the scar group compared with
the normal group, suggesting that participants with two
copies of this haplotype have an increased risk for scars.
Ficek et al. (19) reported that higher frequency of the GT
haplotype was associated with reduced risk of ACL injury.
Yazdanpanah et al. (17) indicated a significantly high
association of the GT haplotype with an increased risk
of fragility fracture in women. Another study suggested
that the GT haplotype of the COL1A1 gene was associated
with a higher risk of postmenopausal osteoporosis in
women from Northwest India (24). These results were in
agreement with a study on COL1A1 haplotypes and hip
fractures, which found a significant association between
the GT haplotype and hip fractures in older people, and
especially in women (26).
Over all, regulatory polymorphisms at the DNA level
can strongly affect variations in gene expression. Any
SNP in the regulatory DNA binding site can modify the
affinity with the regulatory protein, leading to different
levels of gene expression. Promoter polymorphisms are
suspected to affect gene transcription activity, and thereby
gene functions. That, together with the assumption that
the −1997 G/T and +1245 G/T polymorphisms have never
been tested with respect to scars, led us to consider these
polymorphisms separately, as candidates to influence the
risk of sustaining scars. Our results suggested that the
−1997 G/T polymorphism was strongly associated with
the incidence of scars. The −1997 G/T polymorphism
belongs to the proximal promoter elements that modulate
the efficiency of the basal level of transcription.
In conclusion, there was an association between
the –1997 G/T COL1A1 gene polymorphism and scars,
especially in female subjects. No association between scars
and +1245 G/T was found. Although functional analyses
of COL1A1 5’ flank suggested that the GG haplotype was
responsible for enhancing the transcriptional activity of
the COL1A1 gene, we recommend conducting further
investigations, including the evaluation of the type I/type
III collagen ratio, to explain the relationship between
COL1A1 expression and susceptibility to scars.
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